Metformin-associated lactic acidosis and temporary ileostomy: a case report by Margiani, C et al.
JOURNAL OF MEDICAL
CASE REPORTS
Margiani et al. Journal of Medical Case Reports 2014, 8:449
http://www.jmedicalcasereports.com/content/8/1/449CASE REPORT Open AccessMetformin-associated lactic acidosis and
temporary ileostomy: a case report
Carla Margiani1, Luigi Zorcolo1*, Paolo Mura2, Marcello Saba2, Angelo Restivo1 and Francesco Scintu1Abstract
Introduction: Lactic acidosis is a well-known complication of the anti-hyperglycemic biguanide agent metformin,
especially in peculiar but not rare clinical conditions. Attempts to reduce the incidence of this adverse reaction
have been enforced by national agencies over the years. The Italian Medicines Agency recently released a safety
recommendation on prescribing the drug and with regard to the existence of several conditions that contraindicate
drug continuation, such as dehydration, infection, hypotension, surgery or hyperosmolar contrast agent infusion,
but the recommendation does not mention the increased risk related to stoma. The present case report is, to our
knowledge, the first in the literature of metformin-associated lactic acidosis in a patient with a recently created
ileostomy and low anterior resection for rectal cancer.
Case presentation: A 70-year-old Caucasian man who had undergone low anterior resection with total mesorectal
excision and temporary loop ileostomy creation at our institution returned to our department 30 days later because
of nausea, vomiting, diffuse abdominal pain and anuria of about 24 hours’ duration. During his physical examination,
the patient appeared dehydrated and had tachypnea and a reduced level of consciousness. His laboratory tests
showed that he had acute kidney injury and severe lactic acidosis.
Conclusion: An ileostomy puts patients at high risk for output losses that can lead to dehydration and electrolyte
abnormalities. The assessment of the losses through the stoma, especially the ileostomy, should be added to the
recommendations issued by pharmacovigilance societies. The present clinical case illustrates the need for clinicians
on surgical wards to carefully evaluate patients before resuming metformin therapy and to provide appropriate
information at discharge to patients with type 2 diabetes mellitus who have undergone ileostomy. Furthermore, this
case report highlights the increasing need for more training of general physicians regarding both surgical and internal
medicine problems that may arise in the post-operative course after major surgery in patients with co-morbidities.
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Metformin is the recommended first-line therapy for most
patients with type 2 diabetes mellitus (T2DM) [1]. Despite
its being generally safe and associated with a reduction
of cardiovascular events, diabetes-related endpoints and
overall mortality [2], metformin may lead to a rare but
extremely serious adverse reaction: metformin-associated
lactic acidosis (MALA). MALA is defined as a high anion
gap metabolic acidosis with high circulating lactate levels
and without hypoperfusion (type B described by Cohen* Correspondence: gizorcolo@hotmail.com
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45% [4].
On the basis of a suspected increase in the incidence of
MALA [5], the Italian Medicines Agency (AIFA) recently
released and publicized a safety recommendation for
assessment of renal function in patients for whom the
drug is prescribed and suspension of therapy in cases of
dehydration, infection and hypotension, as well as before
surgery or diagnostic procedures involving hyperosmolar
contrast agent infusion [5].
A temporary ileostomy, which is often created to protect
low colorectal anastomoses after radical surgery for colo-
rectal cancer (CRC), is a relatively simple procedure
and is usually well tolerated by the patient. However, ital. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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life-threatening condition in a patient taking metformin.
In this context, we report a case of a patient with
severe MALA that developed after creation of a tempor-
ary loop ileostomy. To the best of our knowledge, no
similar cases have been described in the literature.
Case presentation
A 70-year-old Caucasian man (weight: 75kg; height:
165cm) with T2DM, hypertension and prostatic hyper-
trophy was referred to our unit for CRC treatment. His
usual medications included metformin (3000mg/day),
irbesartan/hydrochlorothiazide 150mg/12.5mg/day and
tamsulosin (0.4mg/day).
Ten weeks after receiving pre-operative chemoradio-
therapy, the patient underwent a low anterior rectal resec-
tion with a diverting ileostomy. Metformin treatment was
suspended 3 days before the operation.
The patient’s post-operative course was uneventful.
His renal function was normal; his blood glucose was
between 150mg/dl and 200mg/dl after a meal; and his
stoma output was approximately 600ml/day.
Metformin therapy was resumed 5 days after surgery,
when the patient returned to a normal diet. He was
discharged to home in good condition on the ninth
post-operative day.
Two weeks later, he returned to our department because
of nausea, vomiting and diffuse abdominal pain. In the
preceding days, he had noticed an increased stoma output
that required him to empty the stoma bag four or five
times per day. He also referred to being anuric for the
preceding 24 hours.
During his examination, the patient appeared dehydrated
and had tachypnea and a reduced level of consciousness.
His blood pressure was 90/60mmHg, and his pulse rate
was 90/min. His laboratory tests showed acute kidney
injury (AKI) (creatinine, 8.94mg/dl; blood urea nitrogen,
324mg/dl) with severe lactic acidosis (pH, 6.99; partial pres-
sure of carbon dioxide, 12mmHg; base excess, −26.9 mM).
Aggressive hydration with crystalloids and intravenous
bicarbonate infusion was initiated. The patient’s internal
jugular vein was cannulated, and he was promptly trans-
ferred to the hemodialysis unit. Hemodialysis was per-
formed for 6 hours and repeated 12 hours later for 3 hours
using bicarbonate-buffered dialysate. His chemical profile
and clinical condition then improved dramatically. His
acidosis resolved over the course of 24 hours; his spontan-
eous diuresis resumed after 48 hours; and his renal function
recovered. The patient was discharged 8 days after admis-
sion with a serum creatinine level of 2.5mg/dl and a blood
urea nitrogen concentration of 50mg/dl. His ileostomy was
closed about 1 month later, and he did not experience any
further similar episodes. At a follow-up examination almost
1 year later, he was well and disease-free.Discussion
The incidence of CRC in older patients is increasing,
resulting in a greater number of patients who present
with concomitant medical illnesses [6]. In a meta-analysis
published in 2005 [7], Larsson and colleagues showed a
relationship between T2DM and an increased risk of
CRC in both women and men (relative risk: 1.30, 95%
confidence interval: 1.20 to 1.40). Further studies have
shown that diabetes is associated with increased risk of
CRC mortality [8,9].
Because of the increasing incidence of its risk factors,
the global prevalence of T2DM is predicted to reach 5.4%
(300 million people) by 2025 [10], and adverse reactions
to drugs commonly prescribed for this condition can be
anticipated to increase accordingly.
MALA is a rare condition. In the largest case series
published in the literature to date, the authors reported no
more than dozens of episodes over years of observation [3].
Nevertheless, taken together, all of the case series point
out the constant association of MALA with predisposing
factors that in various ways affect metformin clearance or
energy metabolism, such as altered renal function, dehy-
dration, other drug interactions, congestive heart failure,
hepatic failure, respiratory failure and drug overdose [3].
A common feature in different case series is that the prog-
nostic effect of drug accumulation is less important than
the seriousness of the underlying medical condition.
Our present case report is, to the best of our knowledge,
the first in the literature of MALA in a patient with a
recently created ileostomy and low anterior resection for
CRC. After ileostomy creation, output usually increases
until the third or fourth day post-operatively. The period
between the fourth and sixth days post-surgery are charac-
terized by stabilizing output. A 7-week period of steady
decrease in volume and thickening of output ensues
[11,12]. Dehydration and electrolyte derangements most
frequently occur in the early post-operative period. In a
recent study, dehydration was found to be the most fre-
quent indication for hospital readmission after diverting
ileostomy creation [13]. In our patient, it is likely that
ileostomy output remained high after discharge without
an oral intake adequate to offset losses. The patient was
also receiving diuretics, which certainly contributed to a
condition of severe dehydration and electrolyte depletion.
Furthermore, the patient continued to take metformin des-
pite having become unwell. Dehydration led to pre-renal
AKI, which was likely worsened by the concomitant con-
sumption of irbesartan, resulting in accumulation of the
drug, hypotension and consequent severe lactic acidosis.
Conclusions
Safety recommendations released by the AIFA in July
2011 dictate metformin contraindications and recommend
assessing renal function when the drug is prescribed. They
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cate drug continuation, such as dehydration, infections,
hypotension, surgery or hyperosmolar contrast agent infu-
sion, but they do not mention the increased risk related to
a stoma. Surgery poses special challenges to patients with
diabetes because of the stress response and interruption of
food intake. Although ileostomy cannot be considered a
direct cause of MALA, it is certainly a high-risk condition
for output losses that often lead to dehydration, electrolyte
abnormalities, vitamin deficiencies and malnutrition. For
these reasons, the assessment of the losses through the
stoma should be added to the recommendations issued
by pharmacovigilance societies. In this setting, ordinary
recommendations regarding ongoing medical therapies
(anti-hypertensive and diuretic treatment in our patient)
should be followed with particular attention to eventual
discontinuation of drugs that put the patient at risk for
dehydration or AKI.
The case that we report illustrates the need for clinicians
on surgical wards to take special care in using metformin
to treat patients with T2DM who have ileostomies. A
careful evaluation is advisable before the resumption of
metformin therapy in these patients, and appropriate
information should be given to the patient at discharge.
Another important aspect that emerges from our case
report is the increasingly urgent need for more training of
general physicians regarding both surgical and internal
medicine problems that may arise in the post-operative
course after major surgery in patients with comorbidities.
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